Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dutabit Plus versus Duodart (dutasteride + tamsulosin)
TCTR20241115008Phase 1Completed
- Sponsor
- International Bio Service
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alpha blocker + 5-alpha reductase inhibitor in benign prostatic hyperplasia (BPH) (2 arms), sponsored by International Bio Service. Started Jul 2025; status: completed.
02
Drugs
alpha blocker + 5-alpha reductase inhibitor
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on TCTR20241115008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241115008.